TY - JOUR
T1 - Clozapine in tardive dyskinesia
T2 - Observations from human and animal model studies
AU - Tamminga, C. A.
AU - Thaker, G. K.
AU - Moran, M.
AU - Kakigi, T.
AU - Gao, X. M.
PY - 1994
Y1 - 1994
N2 - Clozapine has long been considered a useful treatment in patients who have schizophrenia with the neuroleptic-induced delayed-onset side effect tardive dyskinesia. We present data in support of that clinical impression using both an animal model of the disorder and dyskinetic patients themselves. Clozapine produces a lower rate of oral dyskinesia in laboratory rats after 6 months of chronic treatment than does haloperidol (8.6 ± 1.3 vs. 13.6 ± 1.4 vacuous chewing movements every 5 minutes, respectively), suggesting a lower propensity to cause tardive dyskinesia. In the human, when clozapine was compared with haloperidol in the treatment of patients with tardive dyskinesia, clozapine produced significantly greater benefit for motor symptoms after 12 months of treatment than did haloperidol (p < .001). Moreover, the dyskinesia rebound, which occurred equally in both drug groups at the beginning of the study, was sustained in the haloperidol group but lost in the clozapine-treated patients. These data suggest that dyskinetic patients lose their symptoms of tardive dyskinesia, along with dopaminergic hypersensitivity, with long-term clozapine treatment.
AB - Clozapine has long been considered a useful treatment in patients who have schizophrenia with the neuroleptic-induced delayed-onset side effect tardive dyskinesia. We present data in support of that clinical impression using both an animal model of the disorder and dyskinetic patients themselves. Clozapine produces a lower rate of oral dyskinesia in laboratory rats after 6 months of chronic treatment than does haloperidol (8.6 ± 1.3 vs. 13.6 ± 1.4 vacuous chewing movements every 5 minutes, respectively), suggesting a lower propensity to cause tardive dyskinesia. In the human, when clozapine was compared with haloperidol in the treatment of patients with tardive dyskinesia, clozapine produced significantly greater benefit for motor symptoms after 12 months of treatment than did haloperidol (p < .001). Moreover, the dyskinesia rebound, which occurred equally in both drug groups at the beginning of the study, was sustained in the haloperidol group but lost in the clozapine-treated patients. These data suggest that dyskinetic patients lose their symptoms of tardive dyskinesia, along with dopaminergic hypersensitivity, with long-term clozapine treatment.
UR - http://www.scopus.com/inward/record.url?scp=0027984221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027984221&partnerID=8YFLogxK
M3 - Article
C2 - 7961550
AN - SCOPUS:0027984221
SN - 0160-6689
VL - 55
SP - 102
EP - 106
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
IS - 9 SUPPL. B
ER -